Neurocrine Biosciences Inc
1NBIX
Company Profile
Business description
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Contact
6027 Edgewood Bend Court
San DiegoCA92130
USAT: +1 858 617-7600
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,800
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,899.30 | 17.80 | -0.20% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,374.30 | 133.51 | -0.54% |
| NASDAQ | 20,650.13 | 472.31 | -2.24% |
| Nikkei 225 | 40,025.15 | 774.45 | -1.90% |
| NZX 50 Index | 12,724.94 | 4.46 | -0.04% |
| S&P 500 | 6,238.01 | 101.38 | -1.60% |
| S&P/ASX 200 | 8,643.10 | 18.90 | -0.22% |
| SSE Composite Index | 3,553.83 | 6.12 | -0.17% |